Vaccines

A new RNA drug shows promise by reducing harmful belly fat while preserving muscle, but modest overall weight loss in early trials spooks investors.

Early trial data for tazbentetol shows promise in treating schizophrenia by rebuilding synapses, a potential paradigm shift in psychiatric medicine.

Armata Pharmaceuticals posts a staggering $174M annual loss, triggering a 'going concern' alert, yet its promising phage therapy pipeline advances.

SciTech's ST-001 overcomes a decades-old barrier for fenretinide, showing promising results for Cutaneous T-Cell Lymphoma patients in early trials.

Following a 40-year career shaping biotech finance, Jessica Chutter's move to PTC's board signals major strategic ambitions for the rare disease firm.

Experic and Flurry Powders form a strategic alliance to accelerate complex therapies by combining advanced particle engineering with GMP manufacturing.

A new Phase 2 trial is testing an inhaled version of a key IPF drug, aiming to reduce severe side effects and transform treatment for the fatal lung disease.

A key preclinical success in a $570M partnership advances a novel therapy designed to reset the immune system for patients with lupus, MS, and arthritis.

Lifecore Biomedical secures its third major manufacturing deal in five months, signaling a strategic shift that could reshape the aesthetics supply chain.

With key trial enrollment complete, Pyxis Oncology refines its cancer drug MICVO for safety and prepares for pivotal data under a new, seasoned CEO.

UK biotech Amphista to showcase its innovative Targeted Glue™ platform at AACR, revealing new data for AML, lung cancer, and mesothelioma therapies.

With a history of billion-dollar deals, Mark Altmeyer takes the helm at ReproNovo, aiming to commercialize its promising fertility and women's health pipeline.

A novel drug designed to eliminate stubborn cancer proteins enters human trials, offering a new strategy for ALK+ lung cancer patients facing resistance.

With fresh funding secured, Dogwood Therapeutics pushes its promising nerve pain drug, Halneuron®, toward a pivotal data readout later this year.

With a major Series B financing, Crossbow advances its TCR-mimetic therapies, aiming to unlock a new frontier in the fight against a broad range of cancers.

InflaRx announces a late-breaking presentation on its Phase 3 trial for vilobelimab, offering potential new hope for pyoderma gangrenosum patients.

New preclinical data reveals a novel gene therapy that not only kills tumor cells but also boosts immunity, offering hope against drug-resistant lung cancer.

The FDA grants PolyPid a crucial $4.3 million fee waiver for its D-PLEX₁₀₀ drug, freeing up vital cash to accelerate its commercial launch.

After regaining Nasdaq compliance, Incannex Healthcare is leveraging its $75M war chest to advance novel treatments for sleep apnea and anxiety.

Galectin Therapeutics adds legendary neurosurgeon Dr. Henry Brem to its board, a strategic move to leverage his drug development expertise for its lead liver drug.